New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
15:26 EDTGALEGalena responds to article by TheStreet.com
Galena Biopharma issued a letter to its shareholders in response to recent media attention stemming from an article by TheStreet.com. "Dear Shareholders: Due to the recent media attention on Galena Biopharma that we acknowledge is having an impact on investor confidence, we felt it necessary, as a service to our shareholders, to publicly respond to the discussions and set the record straight. The genesis of this attention is due to a single reporter, Adam Feuerstein from TheStreet.com, who clearly has an agenda when it comes to Galena. This can be evidenced by his numerous, tabloid-like articles on the company that have appeared over the past three years and are sensational but largely devoid of true information. The article this week is just another in the line, which for us have become noise. Mr. Feuerstein has never requested a meeting with the company to understand the details of our programs or the goals of the company. On the contrary, his requests for information are consistently accusatory and negative. As a result, we do not feel it is worthwhile to engage him or respond to other media outlets that serve to advance his agenda. However, we do recognize that you, our shareholders, deserve a direct response on the matters at hand. The only facts in Mr. Feuerstein's most recent article that are remotely accurate are that Galena previously engaged the DreamTeamGroup and that insiders at the company, including me, divested shares in mid January. All other accusations in this article as with his prior reporting on Galena are specious and conveniently arranged to create controversy."
News For GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
09:17 EDTGALEOn The Fly: Pre-market Movers
Subscribe for More Information
November 20, 2014
16:22 EDTGALEGalena announces $55M purchase agreement with Lincoln Park Capital
Galena Biopharma announced the execution of a purchase agreement for up to $55M with Lincoln Park Capital Fund, a Chicago-based institutional investor. Under the terms of the purchase agreement dated November 18, LPC initially purchased $5M of Galena common stock at a price of $2.00 per share, 9% higher than the market close as of November 18, 2014. Thereafter, at its sole discretion, Galena may sell up to $50M worth of common stock to LPC over the 36-month term of the purchase agreement, subject to the conditions and limitations set forth in the purchase agreement. Under the terms of the purchase agreement, LPC will not cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of Galena common stock and is obligated to purchase at times and amounts controlled by the company. In consideration for entering into the agreement the company issued shares of its common stock to LPC as a commitment fee. Galena plans to use the proceeds received for its commercial and product development activities and for other working capital and general corporate purposes.
November 18, 2014
07:37 EDTGALEStifel to hold a conference
Subscribe for More Information
07:09 EDTGALEGalena completes enrollment in GALE-401 Phase 2 clinical trial
Galena Biopharma announced the completion of enrollment in the GALE-401, or Anagrelide Controlled Release, Phase 2 Clinical Trial. The Phase 2, clinical proof-of-concept study is treating 18 patients with elevated platelet counts in myeloproliferative neoplasms, or MPNs, including Essential Thrombocythemia, or ET, Polycythemia Vera, or PV, and Primary Myelofibrosis, or PMF. The Phase 2 trial is an open-label, single-arm, multicenter study designed to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure plasma concentrations of anagrelide. The platelet lowering ability of GALE-401 will be measured by the proportion of patients that achieve a complete or partial platelet response for at least four weeks during 24 weeks of treatment. With enrollment complete, patients will now be followed for platelet response while they continue study treatment.
November 11, 2014
09:17 EDTGALEOn The Fly: Pre-market Movers
UP AFTER EARNINGS: FMSA Holdings (FMSA), up 4.7% following third quarter results. ALSO HIGHER: AVEO Pharmaceuticals (AVEO), up 7.6% after entering agreement with Ophthotech (OPHT) to license tivozanib... Ophthotech is 2.1% higher in pre-market trading... Galena Biopharma (GALE), up 3.6% after first patient dosed in NeuVax and Herceptin combination Phase 2 trial... Yamana Gold (AUY), up 3% after being upgraded to Overweight from Neutral at HSBC... Ambac Financial (AMBC), up 3.1% after being upgraded to Neutral from Sell at MKM Partners... China Finance (JRJC), up 12.4% after announcing a new partnership with Great Wall Securities... Zynga (ZNGA), up 5.7% after being upgraded on mobile business growth at Jefferies... Fiat Chrysler (FCAU), up 2.2% after being initiated with a Conviction Buy at Goldman. DOWN AFTER EARNINGS: Applied Optoelectronics (AAOI), down 10.7%... Ekso Bionics (EKSO), down 2.2%. ALSO LOWER: Alibaba Group (BABA), down 1.6% following comments made by vice chairman Joseph Tsai in an interview.
07:06 EDTGALEGalena doses first patient in NeuVax, Herceptin combination Phase 2 trial
Subscribe for More Information
November 10, 2014
13:18 EDTGALEGalena terminates Brian Hamilton as Chief Medical Officer
Subscribe for More Information
November 7, 2014
07:14 EDTGALEGalena presents GALE-301 Phase 1/2a clinical trial data
Galena Biopharma announced that data from the company's Phase 1/2a trial of GALE-301, a Folate Binding Protein, or FBP,-derived immunotherapy, will be presented at the upcoming Society for Immunotherapy of Cancer Annual Meeting. Preliminary data shows a 31% recurrence rate in the vaccine group compared to 50% in the control group at a median follow up of 13 months, a 38% reduction in relative risk of recurrence. GALE-301 plus GM-CSF is well tolerated and elicits a strong in vivo immune response with primarily Grade 1 and Grade 2 toxicities. Top-line data to be presented mid-year 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use